Cellivery Attends JP Morgan Healthcare Conference... "Proposal for Joint Development of COVID-19 Treatment"

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 14th that it will attend the 39th JP Morgan Healthcare Conference held in San Francisco, USA, from January 11 to 14 next year. This event will be held online due to the novel coronavirus disease (COVID-19).

Cellivery will participate in the event to present the therapeutic efficacy and development status of the 'intrinsic immune regulatory antiviral and anti-inflammatory immune therapeutic iCP-NI,' currently being developed as a COVID-19 treatment. A Cellivery official stated, “This event is the optimal opportunity to introduce the COVID-19 therapeutic iCP-NI to global pharmaceutical companies, and we plan to promote joint development and attract investment.”

In addition, the company plans to introduce its platform technology, 'pharmacological substance in vivo delivery technology TSDT.' It will also present efficacy data on the dementia treatment iCP-Parkin, which is being developed using the platform technology. iCP-Parkin has proven to remove deposits of toxic proteins such as amyloid-beta, tau, and alpha-synuclein, which cause Alzheimer's disease and Parkinson's disease, thereby restoring not only motor function but also cognitive function and memory. The accumulated data will be presented at this event.

A Cellivery official said, “At the 2020 JP Morgan event, we secured a comprehensive research collaboration agreement (RCA) with Daiichi Sankyo, Asia’s top innovative pharmaceutical company, and a top 20 Western European pharmaceutical company. Therefore, we expect to conclude new contracts with global pharmaceutical companies currently in negotiation and new partners at next year’s JP Morgan event.”

This content was produced with the assistance of AI translation services.